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ABSTRACT
In an ongoing effort to identify molecular determinants regulating melanoma
brain metastasis, we previously identified Angiopoietin-like 4 (ANGPTL4) as a
component of the molecular signature of such metastases.
The aim of this study was to determine the functional significance of ANGPTL4
in the shaping of melanoma malignancy phenotype, especially in the establishment
of brain metastasis.
We confirmed that ANGPTL4 expression is significantly higher in cells
metastasizing to the brain than in cells from the cutaneous (local) tumor from
the same melanoma in a nude mouse xenograft model, and also in paired clinical
specimens of melanoma metastases than in primary melanomas from the same
patients.
In vitro experiments indicated that brain-derived soluble factors and transforming
growth factor β1 (TGFβ1) up-regulated ANGPTL4 expression by melanoma cells.
Forced over-expression of ANGPTL4 in cutaneous melanoma cells promoted their
ability to adhere and transmigrate brain endothelial cells. Over-expressing ANGPTL4
in cells derived from brain metastases resulted in the opposite effects.
In vivo data indicated that forced overexpression of ANGPTL4 promoted the
tumorigenicity of cutaneous melanoma cells but did not increase their ability to form
brain metastasis. This finding can be explained by inhibitory activities of brain-derived
soluble factors.
Taken together these findings indicate that ANGPTL4 promotes the malignancy
phenotype of primary melanomas of risk to metastasize to the brain.

INTRODUCTION

tumor size, metastasis location, and number of tumor
metastasis [3].
The brain microenvironment consists of several
resident cell types: endothelial cells, astrocytes, microglia,
and neurons. To develop brain metastasis, melanoma cells
must reach the brain vasculature, attach to endothelial
cells covering the microvessel walls, extravasate the brain
endothelium and invade the brain parenchyma, proliferate
and induce angiogenesis [4]. Interactions with brain

Malignant melanoma has a high tendency to develop
brain metastasis [1], conferring upon melanoma patients a
very poor prognosis [2]. As disease management improves
and the survival of melanoma patients is prolonged, the
number of patients that eventually develop clinical brain
metastasis increases. Treatment options are limited beyond
surgery [3] and survival of treated patients depends on
www.impactjournals.com/oncotarget
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RESULTS

microenvironmental cells facilitate metastasis formation.
Astrocytes, for example, interact with tumor cells in the
brain whereby, these interactions may promote metastasis
growth [5, 6]. Furthermore, interaction of glioma initiating
cells with macrophages/microglia up-regulate B7-H4
expression in the latter cells, blocking effective T-cell
immune responses [7]. The molecules and mechanisms
involved in the interactions between melanoma cells and
normal brain microenvironment cells have not been fully
characterized.
We developed human melanoma xenograft models
encompassing cutaneous (local tumor) and melanoma
brain metastasis (MBM) variants originating from single
melanoma tumors [8]. These models have 2 major tumor
biologic relevancies: 1. Both types of variants share a
common genetic background. 2. MBM cells originate
from cells exposed initially to the microenvironment of
the primary tumor and subsequently to the metastatic
microenvironment of the brain while the cutaneous
variants experienced the former microenvironment. This
model enables thus to dissect melanoma characteristics
that were influenced by the microenvironment of the local
cutaneous tumor from those conferred by the metastatic
microenvironment.
Previous experiments using these models indicated
that several genes such as ANGPTL4, CCR4, PTGS2,
MMP1, and PRAME are more highly expressed by human
MBM cells than by the respective cutaneous variants.
Other genes such as ITGA4, CLDN1, CYR61, CDH1, and
IL6R are aberrantly down-regulated in brain metastases
[8, 9]. Our functional studies indicated that claudin-1
(CLDN1) is a MBM suppressor [10] and recently that
CCR4 is a MBM promoter [11].
Angiopoietin-like 4 (ANGPTL4) is a secreted
cytokine member of the angiopoietin family of vascular
regulators [12]. Angiopoietin-like proteins take part in
endothelial cell survival, adhesion and paradoxically,
stimulation or inhibition of angiogenesis and vascular
leakiness [12, 13].
ANGPTL4 acts as a tumor suppressor or promoter
of cancer metastasis, depending on cell type and stage
of cancer [14]. ANGPTL4 regulates diverse malignant
processes. It disrupts vascular endothelial cell-cell
tight junctions (TJ) and adherence junctions, facilitates
trans-endothelial passage of tumor cells, regulates cell
proliferation, apoptosis, angiogenesis, adhesion, motility
and wound healing and acts as an immunosuppressive
factor [12, 15]. ANGPTL4 is also correlated with brain
metastasis relapse in breast cancer [16]. However, some
studies demonstrated the opposite effects [17].
A further investigation is needed using our brain
metastasis model to better understand how the tumor
microenvironment influences the function of ANGPTL4
in early stages of MBM.

www.impactjournals.com/oncotarget

Brain metastasizing melanoma variants overexpress ANGPTL4
In a previous study we showed that MBM variants
of 3 different human melanoma xenograft models express
higher levels of ANGPTL4 than their corresponding
cutaneous variants [8]. These findings were confirmed
in three additional independent melanoma models: by
using Western blot analysis, we assessed ANGPTL4
expression in cutaneous and MBM cells of the parental
human melanoma cells UCLA-SO-M12, UCLA-SO-M16,
and DP-0574-Me. A significant higher expression of
ANGPTL4 was observed in the brain macro-metastatic
variants of these melanomas than in the corresponding
cutaneous variants (P < 0.05) (Figure 1A). Remarkably,
we also identified that ANGPTL4 is up-regulated in
MBM clinical samples. The expression of ANGPTL4
was measured in a cohort of 12 melanoma patients with
paired primary melanoma (PRM), melanoma lymph node
metastasis (LNM), and MBM. Autologous paired triplets
(PRM; LNM; MBM) were derived from 8 patients, paired
duplets (PRM-LNM) or (LNM-MBM) were derived from
3 patients and a single MBM was derived from one patient.
Immunohistochemistry (IHC) staining indicated that LNM
and MBM exhibited significantly higher expression of
ANGPTL4 (P < 0.005 and P < 0.0005, respectively) than
paired PRM, and that MBM exhibited significantly (P <
0.01) higher expression of ANGPTL4 than paired LNM
(Figure 1B, 1C).

ANGPTL4 expression is up-regulated by tumor
growth factor β1 (TGFβ1)
Melanoma cells can secrete high amounts of
TGFβ1, inducing its own expression through a positive
feedback loop [18]. Elevated TGFβ1 plasma levels
have been shown to correlate with melanoma metastatic
progression whereby, this cytokine is known to promote
tumor progression [19]. The TGFβ1 signaling axis
regulates the expression of a variety of genes such as
cytokines, angiogenic factors, extracellular matrix (ECM)
components and cell-surface receptors [12].
We tested whether TGFβ1 regulates ANGPTL4
in cutaneous and MBM cells. Melanoma cells were
stimulated with 5ng/ml TGFβ1 for 4 hrs. Respective
control cells remained untreated. Reverse transcription
quantitative real-time PCR (RT-qPCR) analysis was
performed to determine ANGPTL4 mRNA expression
level. The results showed that TGFβ1 significantly upregulated ANGPTL4 expression in both the cutaneous
and MBM cells (P < 0.05) (Figure 1D). ANGPTL4 upregulation in cutaneous and MBM cells was confirmed at
75779

Oncotarget

Figure 1: ANGPTL4 expression during melanoma progression to brain metastasis. A. ANGPTL4 protein expression level

in UCLA-SO-M12, UCLA-SO-M16 and DP-0574-Me cutaneous (CUT) and melanoma brain metastasizing (MBM) variants of first and
second IC inoculation cycle was analyzed using Western blotting. The obtained values were normalized to β-Tubulin. The bars represent the
relative expression of ANGPTL4 (normalized to RS9), compared to control, untreated cells + SD obtained in one measurement in at least
three independent experiments. *P < 0.05. B., C. ANGPTL4 expression in paired samples of primary melanoma (PRM), melanoma lymph
node metastasis (LNM), and melanoma brain metastasis (MBM) derived from melanoma patients. (B) Representative IHC staining with
anti-ANGPTL4 Ab for PRM, LNM and MBM specimens. Black bars indicate 100µm. The insets show a magnification of the melanoma
lesions. Black arrowheads indicate ANGPTL4 positive melanoma cells. Yellow bars indicate 20µm. (C) Box plot comparing H score
for PRM, LNM and MBM. *P < 0.01, **P < 0.005, ***P < 0.0005. D. Melanoma cells were incubated with 5ng/ml TGFβ1 for 4 hrs.
Following stimulation, RT-qPCR analysis was performed to determine the mRNA expression level of ANGPTL4. The bars represent the
relative expression of ANGPTL4 (normalized to RS9), compared to control, untreated cells + SD obtained in one measurement in at least
three independent experiments. *P < 0.05. E. Brains of BALB/c mice were harvested, and BDF were prepared after 24 hrs (see Materials
and Methods) and added to melanoma cells for 24 hrs at 37°C. Melanoma cells treated with 0.5% BSA supplemented RPMI-1640 served as
control. Following stimulation, RT-qPCR analysis was performed to determine the mRNA expression level of ANGPTL4. The bars represent
the relative expression of ANGPTL4 (normalized to RS9), compared to control, untreated cells + SEM obtained in one measurement in
at least three independent experiments. *P < 0.05. F., G. CM of microglia (MG), astrocytes (HA) and BEC was collected, and added to
YDFR.CB3 (F) and DP.CB2 (G) melanoma cells for 24 hrs at 37°C. Melanoma cells treated with starvation medium served as control.
Following stimulation, RT-qPCR analysis was performed to determine the mRNA expression level of ANGPTL4. The bars represent the
relative expression of ANGPTL4 (normalized to RS9), compared to control, untreated cells + SEM obtained in one measurement in at least
three independent experiments. *P < 0.05, **P < 0.005.
www.impactjournals.com/oncotarget
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Figure 2: ANGPTL4 controls the malignancy phenotype of cutaneous and brain metastasizing melanoma variants. A.-

C. Cutaneous (CUT) and melanoma brain metastasizing (MBM) variants were transduced with an ANGPTL4 cDNA-containing construct
(ANGPTL4hi) or with the backbone construct pQCXIP (CONpQC). MBM cells were transduced with a mixture of 4 different shANGPTL4containing constructs (ANGPTL4lo), or with the control construct (CONsh). The efficacy of ANGPTL4 over-expression or down-regulation
was verified: (A) RT-qPCR analysis was performed to determine the mRNA expression level of ANGPTL4. The bars represent the
relative ANGPTL4 expression (normalized to RS9) in ANGPTL4hi or ANGPTL4lo cells compared to control cells + SEM obtained in one
measurement in at least three independent experiments. *P < 0.05. (B, C) Supernatants of the transduced cells were subjected to Western
blot analysis. ANGPTL4 was detected by specific Abs. The bars represent the relative ANGPTL4 expression in ANGPTL4hi or ANGPTL4lo
cells compared to control cells + SEM obtained in one measurement in two-three independent experiments. *P < 0.05. Representative
blots are shown. Ponceau staining was used for loading control. D., E. Melanoma cells were allowed to migrate through collagen coated
transwells for 24 hrs. The migrated cells were fixed and counted. (D) Representative images are presented (X10 magnification). (E) The
bars represent the average number of migrating cells per field in three independent experiments performed in triplicates + SEM. *P < 0.05.
F. BEC were cultured for 24 hrs to form a confluent monolayer and stimulated with 100 units/ml TNFα and IFNγ for additional 24 hrs.
mCherry- or GFP-expressing melanoma cells were added and allowed to adhere for 30 min at 37°C. The fluorescence signal of labeled
cells was measured before and after removal of non-adherent cells. The bars represent the average % adherent cells (normalized to control
cells) + SEM in at least three independent experiments. Six replicates were performed in each experiment. *P < 0.05. G.-I. BEC were
cultured for 48 hrs on the upper side of the apical chamber of transwell inserts to form a confluent monolayer. Astrocytes were cultured in
24-well plates for 24 hrs and starved for additional 24 hrs to allow the secretion of soluble factors. mCherry-expressing melanoma cells
were added onto the BEC monolayer and allowed to migrate for 24 hrs towards the astrocytes (G). The migrated cells were fixed and
counted. (H) Representative images are presented (X10 magnification). (I) The bars represent the average number of migrating cells per
field (normalized to control cells) in at least three independent experiments performed in triplicates + SEM. *P < 0.05.
www.impactjournals.com/oncotarget
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ANGPTL4 regulates the migratory capacity of
melanoma cells

the protein level after a 24 hrs treatment (in a fold change
of 3.16 and 1.34, respectively) and after a 48 hrs treatment
(in a fold change of 3.59 and 2.8, respectively) with 5ng/
ml TGFβ1, compared to control, untreated cells.

The invasion of cancer cells into surrounding
tissues as well as their intravasation and extravasation
requires migration steered by protrusive activity of the
cell membrane and its attachment to the ECM [20]. Since
ANGPTL4 alters the migratory capacity of several cell
types [13, 21], we examined if ANGPTL4 over-expressing
melanoma cells would manifest an altered ability to
migrate through collagen coated transwells. Cutaneous
ANGPTL4hi cells migrated more efficiently than the
corresponding CONpQC cells (P < 0.05) (Figure 2D, 2E). In
contrast, ANGPTL4hi MBM cells migrated less efficiently
than the corresponding CONpQC cells (P < 0.05).
We also examined if ANGPTL4 down-regulation
alters the ability of melanoma cells to migrate through
collagen coated transwells. The results indicated that
ANGPTL4 knock down in MBM cells does not affect
these tumor cells migratory and invasion ability (Figure
2D, 2E).

ANGPTL4 expression is up-regulated by brainderived factors (BDF)
In order to test whether the brain microenvironment
modulates the expression of ANGPTL4 in melanoma cells,
melanoma cells were subjected to BDF (see Materials
and Methods) for 24 hrs, and then tested for ANGPTL4
expression. In Figure 1E we demonstrated that BDF
significantly up-regulated the expression of ANGPTL4,
compared to its expression in respective control cells
(P < 0.05). ANGPTL4 up-regulation in YDFR.CB3 and
DP.CB2 cells was confirmed at the protein level after a
48 hrs treatment with BDF (in a fold change of 1.5 and
1.46, respectively), compared to control, untreated cells.
In order to examine which cells of the normal brain
environment are the source of the soluble products that
up-regulate ANGPTL4 expression, we performed similar
experiments with conditioned medium (CM) of microglia,
astrocytes, and brain endothelial cells (BEC). Figure 1F
showed that soluble factors of these three cells increased
ANGPTL4 expression in YDFR.CB3 cells (P < 0.05). In
addition, in figure 1G it was demonstrated that soluble
factors of microglia and BEC increased ANGPTL4
expression in DP.CB2 melanoma cells (P < 0.05).

ANGPTL4 regulates the adhesion of melanoma
cells to BEC
In order to disseminate the brain, melanoma cells
must penetrate the brain endothelium. An initial step
in this process is the adhesion of cancer cells to the
endothelium [22]. We therfore evaluated changes in the
capacity of cutaneous and MBM cells over-expressing
ANGPTL4 to adhere to BEC. ANGPTL4hi cutaneous cells
adhered better to BEC than the controls. On the other
hand ANGPTL4hi MBM cells adhered less well to BEC
than the corresponding CONpQC cells (P < 0.05) (Figure
2F). We also determined the adherence capacity of GFPexpressing ANGPTL4lo MBM cells and of CONsh cells to
BEC. ANGPTL4lo MBM cells adhered better to BEC (P
< 0.05) than their corresponding CONsh cells (Figure 2F).
Taken together these results indicated that ANGPTL4 is a
determinant of the adherence capacity of melanoma cells
to BEC. Whereas ANGPTL4 promotes the adhesion of
cutaneous cells to BEC it reduces the adhesion of MBM
cells to BEC.

Overexpression or knockdown of ANGPTL4 in
melanoma cells
Cutaneous and MBM cells were infected with
virions composed of constructs containing ANGPTL4
cDNA, to establish cell populations over-expressing
ANGPTL4 (ANGPTL4hi cells). The same cells, infected
with virions containing a mock plasmid, were used as
control (CONpQC). Over-expression of ANGPTL4 was
validated using both RT-qPCR and Western blotting
(Figure 2A, 2B). To down-regulate endogenous ANGPTL4
expression, we infected MBM cells with virions containing
a mixture of four different shANGPTL4-pGIPZ plasmids
(ANGPTL4lo).
Using RT-qPCR and Western blotting we examined
these four plasmids for their efficacy to down-regulate the
expression of this protein (data not shown). A mixture of
the four vectors was used to maximize ANGPTL4 knock
down as it showed the strongest effect (Figure 2A, 2C).
The same cells, infected with virions containing shnon-silencing pGIPZ vector, were used as control (CONsh).

www.impactjournals.com/oncotarget

ANGPTL4
regulates
melanoma
transmigration through BEC

cell

In a previous study we demonstrated that astrocytes
have the capacity to chemo-attract melanoma cells thereby
enhancing their ability to transmigrate through BEC [5].
We therefore evaluated whether ANGPTL4 affecs the
transendothelial migration (TEM) of melanoma cells
in a blood-brain barrier (BBB) model simulating the
extravasation of melanoma cells through BEC towards
75782
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astrocytes. Figure 2H, 2I showed that ANGPTL4 overexpression significantly enhanced the ability of m-Cherry
labeled cutaneous melanoma cells to migrate towards

astrocytes through BEC (P < 0.05). In contast, ANGPTL4
over-expression attenuated the TEM of MBM cells (P <
0.05). MBM cells in whom ANGPTL4 was knocked down

Figure 3: Secretion of bioactive factors from melanoma cells is dependent on ANGPTL4 expression level. A.-C.

Melanoma cells were cultured for 24 hrs, then starved for additional 24 hrs, to allow secretion of melanoma-soluble factors. CM was
collected and added to BEC. Cell viability of BEC grown with CM of cutaneous CONpQC and ANGPTL4hi melanoma cells (A) or MBM
CONpQC and ANGPTL4hi melanoma cells (B) was monitored after 24, 48 and 120 hrs. Cell viability of BEC grown with CM of MBM
CONsh and ANGPTL4lo melanoma cells (C) was monitored after 72 hrs. Viability was determined using XTT-based assay. Absorbance at
450 nm was determined for each well, and subtraction of nonspecific readings (measured at 630 nm) was calculated. The bars represent
the average viability of the BEC grown with ANGPTL4hi or ANGPTL4lo melanoma CM relative to those grown in control melanoma CM
+ SD in three independent experiments. Six replicates were performed in each experiment. *P < 0.05, **P < 0.005. D.-G. Melanoma
cells were seeded for 24 hrs and then cultured in serum-free media for additional 24 hrs. CM were collected and subjected to gelatin
and collagen zymography. (D, F) Images of one representative experiment out of three are presented. A ~66 kDa band indicating the
active form of MMP-2 was observed. (E, G) The bars represent the average MMP-2 activity (pixel density) as measured by densitometry,
normalized to control cells + SD in one measurement in three independent experiments . *P < 0.05, **P < 0.0.1, ***P < 0.005. H., I. BECs
were treated with melanoma CM for 24 hours. Then, CLDN1 expression was analyzed using RT-qPCR and flow cytometry. (H) The bars
represent the relative CLDN1 mRNA expression (normalized to RS9) compared to control cells + SD obtained in one measurement in
least three independent experiments. *P < 0.05. (I) BEC were trypsinized and analyzed for CLDN1 expression using flow cytometry. Dot
plot histogram comparing % CLDN1 positive BEC. Each dot represents the value obtained in a single independent experiment. The line
represents the average value in each variant. **P < 0.01.
www.impactjournals.com/oncotarget
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Secretion of factors that differentially modify the
viability of BEC

(ANGPTL4lo cells) transmigrated more efficiently towards
astrocytes through BEC than the corresponding CONsh
cells (P < 0.05).
The above results indicated that ANGPTL4 is
functionally involved in the migration and TEM of
melanoma cells. Whereas ANGPTL4 enhanced TEM of
cutaneous melanoma cells through the blood brain barrier,
it reduced TEM of the MBM cells through the blood
brain barrier. The observation that ANGPTL4 influenced
differentialy the ability of cutaneous and MBM cells to
transmigrate through BEC layers may be due, at least in
part, to the differential capacity of the two types of cells to
adhere to brain-derived endothelium.
An alternative explanation is that when overexpressed by the MBM cells, ANGPTL4 may increase
the stability of endothelial junctions and thus increase
endothelial cell barrier integrity, as demonstarted by
Bouleti et al [23].

Endothelial cell status and growth is a crucial factor
in angiogenesis [24] whereby the cross-talk between tumor
and endothelial cells contributes to these functions. To
determine whether ANGPTL4 overexpressing melanoma
cells differ from control cells in the ability to sustain the
viability of BEC, BEC were treated with CM of CONpQC
or ANGPTL4hi cutaneous and MBM cells. XTT assays
indicated that CM of ANGPTL4hi cutaneous melanoma
cells decreased the viability of BEC (compared to the
viability of BEC exposed to CM of CONpQC melanoma
cells), at 48 and 120 hrs of exposure (P < 0.05 and P <
0.005, respectively) (Figure 3A).
On the other hand at 120 hrs of exposure, CM of
ANGPTL4hi MBM cells increased the viability of BEC

Figure 4: ANGPTL4 alters the tumorigenic potential of melanoma cells. A. Volume of cutaneous tumors following subdermal

implantation of CONpQC vs. ANGPTL4hi cutaneous cells. Tumor dimensions were measured using a caliper and volume was obtained as
described in Materials and Methods. The average tumor volume + SEM is presented. *P < 0.05. B. Mice were weighed weekly following
melanoma inoculation. The averege mouse weight + SD is presented. *P < 0.05. C. Melanoma cells were treated for 72 hrs with mouse
BDF. Then, cells were trypsinized and cell death was determined by measuring DAPI incorporation. The bars represent the relative cell
death of BDF treated cells compared to their controls + SEM obtained in one measurement in three independent experiments. *P < 0.05.
www.impactjournals.com/oncotarget
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compared to that of BEC exposed to CM of CONpQC cells
(P < 0.05) (Figure 3B).
Similar experiments were performed with CM of
CONsh and ANGPTL4lo MBM cells. At 72 hrs of exposure
the viability of BEC exposed to CM of ANGPTL4lo brain
metastatic melanoma cells was lower than the viability of
BEC exposed to CM of CONsh cells, (P < 0.05) (Figure
3C).
Taken together these results demonstrated that
ANGPTL4 expressed by cutaneous melanoma cells
induces or up-regulates secretion of soluble factors that
inhibit BEC growth. In contrast ANGPTL4 in MBM
cells induces or up-regulates secretion of soluble factors

that promote BEC growth. This indicates the ANGPTL4
expression effect is context dependent on the source of the
melanoma cell.

Secretion of active matrix metalloproteinase-2
(MMP-2)
Invasive growth of cancer cells requires local
proteolysis, which is mediated by locally secreted
MMPs. These enzymes participate in ECM degradation
during metastasis, and are essential for basementmembrane penetration [25]. An increased expression of

Figure 5: Proteomic expression analysis of ANGPTL4 high and low expressing cells. The expression of 305 proteins was

examined using RPPA analysis in the ANGPTL4hi and ANGPTL4lo cells vs. their corresponding control cells. A., B., C. Comparisons were
done for each pair of cells: (A) cutaneous ANGPTL4hi vs. CONpQC cells, (B) brain metastasizing ANGPTL4hi vs. CONpQC cells and (C) brain
metastasizing ANGPTL4lo vs. CONsh cells. The tables show the normalized expression of differentially expressed proteins with FC < -1.25
or FC>1.25. D., E. Venn diagrams were used to compare lists of differentially expressed proteins. (D) Proteins differentially expressed in
both comparisons obtained in (A) and (B). (E) Proteins differentially expressed in both comparisons obtained in (B) and (C). F. Proteinprotein interactions of differentially expressed proteins with FC < -1.5 or FC>1.5 from all three comparisons. Circled in blue are proteins
from comparison (A), circled in orange are proteins from comparison (B), and circled in green are proteins from comparison (C).
www.impactjournals.com/oncotarget
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MMP proteins, such as MMP-2 in tumor cells is often
accompanied with increased invasiveness and metastasis,
as well as with decrease in overall survival [26].
To determine if ANGPTL4 is involved in the
regulation of MMP-2 activity, we performed gelatin and
collagen zymography assays comparing cutaneous and
MBM cells overexpressing ANGPTL4 (ANGPTL4hi) with
appropriate control cells (CONpQC).
Whereas CONpQC and ANGPTL4hi cutaneous cells
secreted higher levels of active collagen degrading MMP2 (P < 0.05) (Figure 3F, 3G), ANGPTL4hi MBM cells

secreted significantly lower levels of active gelatin and
collagen degrading MMP-2, than CONpQC cells (P < 0.01
and P < 0.0005, respectively) (Figure 3D-3G).
We next examined if ANGPTL4 down-regulation
in melanoma cells affects MMP-2 secretion. Gelatin
zymography assays comparing the CONsh and ANGPTL4lo
MBM cells showed that ANGPTL4lo MBM cells secreted
higher levels of active gelatin degrading MMP-2 than
CONsh cells (P < 0.005) (Figure 3D, 3E).
Taken together, these results imply that ANGPTL4
inhibits MMP-2 activity in MBM cells, while it has an

Figure 6: A proposed mechanism for ANGPTL4-mediated melanoma malignancy progression. A soluble factor in the

microenvironment of the primary tumor transforming growth factor β1 (TGFβ1) induces the expression of ANGPTL4 in primary melanoma
tumor cells. ANGPTL4 enhances their ability to migrate through extracellular matrix (ECM) components and to adhere and invade brain
vasculature, for example by down-regulating the expression of cell-cell adhesion tight junction (TJ) molecules such as claudin-1 (CLDN1).
Once arriving the brain, brain-derived soluble factors secreted by microglia, brain endothelial cells (BEC) and astrocytes, induce ANGPTL4
expression by brain metastasizing cells, what contributes to different phenotypes, such as resistance against brain-derived cytotoxic factors,
enhancement of BEC growth and induction of angiogenesis-related genes such as angiopoietin 1 (ANG1) (data not shown) in BEC subjected
to factors released from brain metastasizing cells, expressing high ANGPTL4 levels.
www.impactjournals.com/oncotarget
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The effects of BDF on melanoma cell viability is
ANGPTL4-dependent

inducing effect on MMP-2 activity in the cutaneous cells.
This suggests that ANGPTL4 contributes to melanoma cell
invasion from the primary tumor to enhance metastatic
spread.

Once extravasating to the target organ, metastasis
propagation depends on the ability of disseminated
tumor cells to survive and proliferate in their new
microenvironment. Several studies showed that ANGPTL4
is a regulator of cell proliferation [28]. We previously
demonstrated that BDF promote the viability of cutaneous
melanoma cells but induce cell death of MBM cells [29].
In order to find out whether ANGPTL4 levels play a
role in the differential susceptability of the cutaneous and
MBM cells to these soluble factors, we examined the effect
of BDF on the viability of melanoma cells, expressing
high or low levels of ANGPTL4. ANGPTL4hi and
CONpQC cutaneous melanoma cells and ANGPTL4lo and
CONsh MBM cells were treated with BDF or starvation
medium (control) for 72 hrs. Cell death was determined by
4’,6-Diamidino-2-phenylindole dihydrochloride (DAPI)
incorporation measurement. Figure 4C demonstrates that
BDF protected CONpQC cutaneous cells (low ANGPTL4
expressing) from spontaneous cell death. On the other
hand BDF induced cytotoxicity in ANGPTL4hi cutaneous
cells. These experiments lead us to conclude that a high
expression of ANGPTL4 in the cutaneous cells sensitizes
these melanoma cells to cytotoxicity mediated by BDF.
BDF treatment of MBM cells expressing relatively
high levels of endogenous ANGPTL4 (CONsh) induced
cell death. Treating MBM cells expressing reduced levels
of ANGPTL4 (ANGPTL4lo) with BDF, resulted in further
induction of cell death. Expression of ANGPTL4 in the
MBM cells protects these melanoma cells from death
exerted by BDF, increasing their sustainability in the brain
microenvironment.

Secretion of factors that differentially decrease
expression of CLDN1 by BEC
As ANGPTL4 reprograms endothelial permeability
[15, 27] we asked if melanoma-associated ANGPTL4
regulates either directly or indirectly the integrity of TJs
in BEC. We utilized RT-qPCR and flow cytometry to
measure the expression of CLDN1, a TJ protein known to
be expressed on the BEC [10]. BEC were treated with CM
of CONpQC or of ANGPTL4hi cutaneous and MBM cells.
Figures 3H and 3I show that CM of ANGPTL4hi cutaneous
cells down-regulated CLDN1 expression (P < 0.05),
while CM of ANGPTL4hi MBM cells did not significantly
alter the expression of this TJ protein, compared to the
corresponding control cells. CM of ANGPTL4lo MBM
cells also did not alter CLDN1 expression compared
to the corresponding control cells. This suggests that
ANGPTL4 contributes to melanoma cell passage through
BBB junctions.

In vivo functios: ANGPTL4 enhances melanoma
tumorigenicity
The question if and how ANGPTL4 is involved
in the shaping of the in vivo malignancy phenotype of
melanoma cells was examined. Local tumor formation
was assessed in nude mice orthotropically inoculted with
CONpQC or with ANGPTL4hi cutaneous human melanoma
cells.
An orthotopic inoculation of ANGPTL4hi cutaneous
cells resulted in a significantly enhanced tumor growth
compared to inoculation of CONpQC cutaneous cells (P <
0.05) (Figure 4A). Mice inoculated with the ANGPTL4hi
cutaneous cells weighed less than those inoculated with the
CONpQC cutaneous cells, indicating the highly malignant
phenotype of the desease (P < 0.05) (Figure 4B).
We next asked whether ANGPTL4 over-expression
in cutaneous melanoma cells would influence the capacity
of such cells to form spontaneous brain micro-metastasis.
Nude mice were inoculated orthotopically with control
(CONpQC) cutaneous melanoma cells or with cells
overexpressing ANGPTL4 (ANGPTL4hi ). The mice were
killed 65 days post inoculation and anaylzed, by RT-qPCR
using human specific primers, for the presence of human
melanoma micro-metastastais. No significant differences
were found in the incidence of MBM between the two
groups: CONpQC cells (brains of 10 mice out of 15 were
positive for melanoma cells) and ANGPTL4hi cells (brains
of 7 mice out of 16 were positive for melanoma cells) .
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Reverse Phase Protein Array (RPPA) analysis
of melanoma cells differentially expressing
ANGPTL4
In the next set of experiments we examined the
effect of ANGPTL4 over-expression or knock-down on
protein expression profile in melanoma cells. To this end
we compared RPPA data of ANGPTL4 overexpressing
(ANGPTL4hi) cutaneous melanoma cells and MBM
cells with the corresponding control (CONpQC) cells. For
each pair of cells we established a list of proteins which
were differentially expressed in a FC < -1.25 or FC>1.25
(Figure 5A, 5B, respectively). Identifying the differentially
expressed proteins may highlight the mechanism by
which ANGPTL4 regulates the malignancy phenotype of
melanoma cells.
We observed 27 proteins that were differentially
expressed in the cutaneous melanoma cell pair (YDFR.CANGPTL4hi vs. YDFR.C-CONpQC) comparison (Figure
5A). This list of proteins includes CD171 (L1CAM),
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which is up-regulated (FC=1.6) in ANGPTL4hi cells.
L1CAM has a role in metastatic cell spreading along
brain capillaries and in metastatic outgrowth [30]. Another
up-regulated protein is monocarboxylate transporter 4
(MCT4; FC=2.01), a lactate transporter, whose expression
was found to be increased with melanoma progression
from nevi to advanced metastatic disease [31].
We observed 25 proteins that were differentially
expressed in the MBM cell pair (YDFR.CB3-ANGPTL4hi
vs. YDFR.CB3-CONpQC) (Figure 5B). This list of proteins
includes the von Hippel-Lindau tumor suppressor (VHL),
down-regulated (FC=-1.43) in the ANGPTL4hi cells.
RPPA analysis was also performed to establish the
effect of ANGPTL4 knock-down on protein expression
profile of the MBM cell pair (YDFR.CB2-ANGPTL4lo
vs. YDFR.CB2-CONsh). RPPA analysis yielded a list of
22 proteins that were differentially expressed in a FC <
-1.25 or FC>1.25 (Figure 5C). This list of proteins include
connexin-43 (FC=-1.34), whose inhibition promotes
melanoma cell proliferation [32].
Venn diagram analysis was performed to provide
a list of shared differentially expressed proteins that are
altered in the cutaneous and MBM ANGPTL4 overexpressing cells compared to their controls (Figure
5D). 6 proteins were identified in both lists: ALDH1A1,
β-catenin, E-Cadherin, Gab2, Stat5a and vimentin. These
proteins are all either up-stream or down-stream to
epithelial to mesenchymal transition (EMT) regulators in
tumor cells [33-36]. This may imply that EMT constitutes
a mechanism by which ANGPTL4 is involved in
melanoma progression. Most interesting proteins are those
that show an opposite trend of alteration in the cutaneous
vs. the MBM pairs, in correspondence to the opposite pro/
anti-malignancy effects of ANGPTL4 over-expression
observed in the experiments above. Five of these proteins:
E-Cadherin, GRB2-associated-binding protein 2 (Gab2),
Stat5a, vimentin, and β-catenin were differentailly
expressed in the two comparisons in an opposite manner.
Venn diagram analysis was also performed to
provide a list of shared differentially expressed proteins
that are altered following ANGPTL4 over-expression
and knock-down in the metastatic variants (Figure 5E).
Six proteins appeared in both comparisons: ACC_pS79,
ALDH1A1, CDK1, E-Cadherin, PDGFR-beta, and
Vimentin. PDGFR-beta was differentially expressed in
the two comparisons in an opposite manner. These results
imply again that EMT may be involved in ANGPTL4mediated melanoma progression, due to the observed
changes in the expression of these proteins, all of which
are either up-stream or down-stream to EMT regulation in
tumor cells [37-39].
Network of protein interactions was created for
proteins differentially expressed in a FC < -1.5 or FC>1.5
from the three comparisons using STRING (Figure 5F).
The biological processes ascribed to these differentially
expressed proteins include: kinase activity, metabolism,
www.impactjournals.com/oncotarget

proliferation and apoptosis, all of which have relevance
in metastasis.

DISCUSSION
Metastasis is the major cause leading to death
from cancer. Treating metastasis is complex since
frequently it has already occurred by the time the disease
was diagnosed [40]. The growth and progression of
metastasis is dependent on the tumor autonomous traits
as well as on the interactions of the cancer cells with
microenvironmental cells in their vicinity and with soluble
factors released or secreted by them [40-45]. However,
relatively little information exists on the interaction of
constituent normal brain cells of tumor microenvironment
with brain metastasis. Understanding the molecular basis
for the spread of melanoma to the brain and the cellular
interactions within the microenvironment is necessary
for the development of novel therapeutic and prognostic
solutions for this disease.
This study showed that ANGPTL4 is more highly
expressed in MBM cells than in corresponding cutaneous
melanoma cells in human MBM models as well as in
clinical samples. Interestingly, MBM exhibited higher
expression of ANGPTL4 than paired LNM. This result
emphasizes the importance and selectivity of ANGPTL4
for metastasis propagation in the brain.
We have demonstrated that soluble factors in the
brain microenvironment, including those secreted by
microglia, astrocytes and brain endothelium, up-regulate
ANGPTL4 expression. The exact soluble components
of the brain which are responsible for ANGPTL4 upregulation were not yet characterized. One of the candidate
factors is TGFβ1, known to be up-regulated in the injured
or inflamed brain [46-49].
The increase in ANGPTL4 expression, may, at
least in part, be attributed to TGFβ1 stimulation. Cancer
cells, including melanomas, tend to selectively utilize the
beneficial functions of TGFβ signal transduction, including
ANGPTL4 up-regulation (via the Smad signaling
pathway), while eliminating the tumor suppressor function
downstream to TGFβ [50, 51]. In ER negative breast
tumors, TGFβ induces ANGPTL4 expression, thereby
priming tumor cells for lung metastasis. This is enabled
by microenvironmental TGFβ that induces or upregulates
ANGPTL4 expression in disseminating tumor cells on
their way to secondary metastatic sites. The upregulated
ANGPTL4 enables tumor cells to disrupt vascular
endothelial junctions when arriving the lung capillaries,
thereby facilitating their trans-endothelial passage [50,
51]. A similar mechanism may operate in the case of
MBM, as we have demonstrated that ANGPTL4 increases
the ability of melanoma cells to penetrate brain endothelial
cell monolayer.
To investigate the involvement of ANGPTL4 in
melanoma malignancy, we have established cutaneous
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and MBM cells in which ANGPTL4 is overexpressed and
MBM cells in whom ANGPTL4 is knocked-down.
The results demonstrated that like certain other
genes [52, 53], ANGPTL4 plays a yin-yang role depending
on tumor stage; it promotes malignancy of cutaneous
melanoma cells and ameliorates the malignant phenotype
of brain-metastasizing cells.
In the early phases of the metastatic cascade,
when the tumor cells are still outside the brain
microenvironment, over-expression of ANGPTL4 in
the cutaneous cells promoted characteristics that would
enable their invasion to the target organ, the brain
microenvironment. These malignancy-promoting activities
included increase in the volume of the primary tumor,
increased MMP activity, promoting migration through
ECM, adhesion to BEC and penetration through a brain
endothelial layer towards astrocytes. Stimulation of
BEC with CM of ANGPTL4 over-expressing cutaneous
melanoma cells down-regulated the expression of CLDN1,
a TJ protein involved in cell adhesion.
Un-expectedly and in contrast to the enhanced
ability of ANGPTL4 overexpressing cutaneous cells to
form local tumors, their ability to form brain metastasis
was not promoted. Based on the results summarized
above, the following scenario may account for these
seemingly contradictory findings: In view of the fact
that ANGPTL4 overexpression enhances migration and
transmigration of cutaneous melanoma cells through the
BBB, such cells would preferentially localize in the brain.
However ANGPTL4 overexpressing cutaneous melanoma
cells are sensitive to the cytotoxic activity of BDF which
would diminish metastasis.
BDF, as described in the Materials and Methods
section is a mixture of soluble factors released from
the brain of BALB/c mice incubated for 24 or 48 hrs
(depending on the experiment) at 37°C. This method of
preparation was developed by Maman et al. from our
laboratory [54, 55] who prepared lung derived factors
which restrained the proliferation of lung metastasis.
Preliminary, unpublished experiments indicated that the
BDF is a protein with a molecular weight above 3.5kDa.
In the future we plan to identify the active factors in
the BDF, that affect melanoma cell viability and other
observed phenomena (i.e. ANGPTL4 expression).
Over-expression of ANGPTL4 in the MBM cells
moderates the malignancy-promoting activities. Downregulation of ANGPTL4 in MBM cells yielded, in
general, compatible results to those reported above: The
malignancy phenotype of these cells was promoted. MBM
cells with down-regulated levels of ANGPTL4 adhered
better to BEC, secreted higher levels of active MMP-2 and
penetrated more efficiently through the BBB.
The scenario taking place at later stages of
metastasis when melanoma cells have already penetrated
the tumor microenvironment of the brain is different.
Cancer cells must be able to survive and proliferate in
www.impactjournals.com/oncotarget

order to establish the metastatic foci. Cells should have
the ability to avoid cell death and to promote angiogenesis,
necessary for nutrient and oxygen supply. For angiogenesis
to occur, endothelial cells must migrate and proliferate at
the distant metastatic site [24].
MBM cells, expressing high levels of endogenous
ANGPTL4 (CONsh cells), are less sensitive to the viability
restraining function of BDF then the same cells with
down-regulated ANGPTL4 expression (ANGPTL4lo
cells). ANGPTL4 may thus protect such cells from BDF
mediated death.
Soluble factors from MBM cells over-expressing
ANGPTL4 had a growth promoting effect on BEC. Downregulation of ANGPTL4 in the MBM cells resulted in
reduced BEC viability. Therefore, ANGPTL4 expressed
by MBM cells may support angiogenesis in the brain. This
possibility will be further investigated in the future.
The experiments described above demonstrate that
ANGPTL4 expression level has a significant involvement
in melanoma-BEC interactions, and that autocrine effects
of ANGPTL4 on melanoma cells may result in paracrine
effects on BEC.
As indicated above, TGFβ1 induced ANGPTL4
expression in melanoma cells. Interestingly, RPPA analysis
of high vs. low ANGPTL4 expressing melanoma cells
demonstrated that most differentially expressed proteins
are either up-stream or down-stream of the EMT cascade,
which is classically controlled by the TGFβ pathway.
Further investigation is aimed to elucidate the mechanism
by which ANGPTL4 regulates these proteins. It is not
unlikely that similarly to how ANGPTL2 and TGFβ1
positively increase the expression of each other in chronic
kidney disease [56], ANGPTL4 and TGFβ1 employ such
reciprocal effects on each other expression.
Taken together our study demonstrates that
whereas ANGPTL4 promotes the malignancy phenotype
of cutaneous melanoma cells in early stages of brain
metastasis, it ameliorates the malignancy phenotype of
MBM cells in the later stages of brain metastasis, when
the brain tumor microenvironment plays a significant
functional role in disease progression. The data presented
is in agreement with studies showing that the expression
and roles of ANGPTL4 are context and tumor stage
dependent, and that ANGPTL4 has a diverse role in
metastasis [34].
We propose a mechanism for brain metastasis
(illustrated in Figure 6) whereby a soluble factor in the
microenvironment of the primary tumor (e.g. TGFβ1)
induces the expression of intracellular or extracellular
proteins (e.g. ANGPTL4) in cells of the primary tumor.
These cells are able to migrate through ECM, adhere
to and invade brain vasculature, for example by downregulating the expression of cell-cell adhesion TJ
molecules such as CLDN1 [57, 58]. Once in the brain,
angiogenesis promotion, endothelial proliferation
and survival may have a higher priority rather than
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Western blotting

characteristics such as adhesion and invasion. Therefore
in MBM cells, high expression of ANGPTL4 (induced by
brain-derived soluble factors) may contribute to different
phenotypes, such as resistance against brain-derived
cytotoxic factors, enhancement of BEC growth and
induction of angiogenesis-related genes such as ANG1
(data not shown) in BEC subjected to factors released
from MBM cells which express high levels of ANGPTL4.

Cells were plated in growth medium for 24 hrs.
For the detection of secreted ANGPTL4, supernatants
were collected, centrifuged at 1400 rpm for 5 min and
filtered (0.45µm). For the detection of intracellular
ANGPTL4, the plated cells were washed twice with
ice-cold PBSX1 and lysed (20mM Tris pH 8, 250mM
NaCl, 0.5% Nonident p-40 (NP-40), 5mM EDTA pH
8, 4mM EGTA pH 8, 20mM sodium phosphate pH 7.6,
3mM β glycerol phosphate, 2mM sodium orthovanadate
(Na3VO4), 5mM NaF, 10mM sodium pyrophosphate
pH 7.6, 2 µg/ml aprotinin, 2 µg/ml leupeptin and 1mM
phenylmethylsulfonyl (PMSF) supplemented with DDW).
Cell lysates were incubated for 20 min on ice and cleared
by centrifuging at 16,000g for 20 min at 4°C. Pierce
BCA protein assay kit (Thermo Scientific, Rockford, IL,
USA) was used to determine protein concentration. After
the addition of Laemmli sample buffer, the lysates or
supernatants were resolved on SDS-PAGE, and transferred
onto nitrocellulose membrane. The total amount of protein
in the lanes was assessed by Ponceau staining prior to
blocking of the membrane. The membranes were blocked
at room temperature with 3% BSA diluted in TBS-Tween
for 1 hr. For detection of the target proteins, membranes
were incubated with relevant primary antibodies: Antihuman ANGPTL4 antibody (Ab) (1:350, R&D Systems,
Inc., Minneapolis, MA, USA) and rabbit polyclonal to beta
Tubulin (1:500, Abcam, Cambridge, UK). Horseradish
peroxidase-conjugated donkey anti-goat or goat anti-rabbit
(1:10000, Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) were used as secondary Ab.
The bands were visualized by chemoluminescenceECL reactions and autoradiography by exposure to Fuji
film. The amount of the relevant protein in the lanes was
estimated by densitometry using Quantity One Image
software.

MATERIALS AND METHODS
Animals
Male BALB/c mice were purchased from Tel Aviv
University animal facility. Male athymic nude mice
(BALB/c background) were purchased from Harlan
Laboratories Limited (Israel). The mice were housed
and maintained in laminar flow cabinets under specific
pathogen-free conditions in the animal quarters of TelAviv University and in accordance with current regulations
and standards of the Tel-Aviv University Institutional
Animal Care and Use Committee. The mice were used
when they were 7-8 weeks old.

Cell culture
The production and maintenance of cutaneous
human melanoma variant (YDFR.C) and MBM variants
(YDFR.CB2 and YDFR.CB3) were described previously
[8].
Novel xenograft models were obtained from the
parental cell lines UCLA-SO-M12, UCLA-SO-M16 and
DP-0574-Me (JWCI) as we described previously for
the YDFR cells [8], and consist of cutaneous variants
(C variants) and brain macro-metastatic variants (CB1
and CB2 variants; the number represents the number of
cycles of re-inoculation into the left ventricle of the heart
as described previously [8]). Human embryonic kidney
293T cells were maintained as described previously [10].
Immortalized human brain microvascular endothelial cells
(hCMEC/D3) were kindly provided by Dr. Clara Nahmias
and Prof. Pierre-Olivier Couraud (Inserm, U1016,
Institut Cochin, Paris, France) and were maintained as
described by Weksler et al [59]. Human astrocytes were
maintained as described previously [5]. Immortalized
human microglia-SV40 cell line was purchased from
ABM (ABM, Milton, Canada) and were maintained on
100μg/ml collagen I, rat tail (BD Biosciences, Bedford,
MA, USA) in 10% fetal calf serum (FCS) supplemented
Prigrow III medium (ABM).
0.5% FCS supplemented medium was used for
starvation in all the experiments, unless indicated
otherwise. Cells were routinely cultured in humidified air
with 5% CO2 at 37°C.
www.impactjournals.com/oncotarget

Flow cytometry
CLDN1 expression was analyzed by monoclonal
anti-human CLDN1 Ab (1μg/sample, R&D Systems),
using flow cytometry as described previously [9].
Fluorescein isothiocyanate (FITC)-conjugated goat antirat IgG (1:50, Jackson ImmunoResearch Laboratories)
was used as secondary Ab.
Antigen expression was determined using Becton
Dickinson FACSort (Becton Dickinson Mountain View,
CA, USA) and CellQuest software. Dead cells were gated
out from the analysis.
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Immunohistochemistry (IHC)

by CSA amplification approach and visualized by DAB
colorimetric reaction.
Slides were scanned on a flatbed scanner to
produce 16-bit tiff images. Spots from tiff images were
identified and the density was quantified by Array-Pro
Analyzer. Relative protein levels for each sample were
determined by interpolation of each dilution curve from
the “standard curve” (supercurve) of the slide (Ab).
Supercurve is constructed by a script in R written by
Bioinformatics (“Supercurve Fitting” developed by the
Department of Bioinformatics and Computational Biology
in MD Anderson Cancer Center, http://bioinformatics.
mdanderson.org/Software/supercurve). Each dilution
curve was fitted with a logistic model. This fits a single
curve using all the samples (i.e., dilution series) on a slide
with the signal intensity as the response variable and the
dilution steps are independent variable. The fitted curve
(“supercurve”) was plotted with the signal intensities on
the Y-axis and the relative log2 concentration of each
protein on the X-axis using the non-parametric, monotone
increasing B-spline model. During the process, the raw
spot intensity data were adjusted to correct spatial bias
before model fitting. A QC metric was returned for each
slide to help determine the quality of the slide: if the score
is less than 0.8 on a 0-1 scale, the slide was dropped. In
most cases, the staining was repeated to obtain a high
quality score. The protein concentrations of each set of
slides were then normalized by median polish, which was
corrected across samples by the linear expression values
using the median expression levels of all Ab experiments
to calculate a loading correction factor for each sample.
These values (given as log2 values) are defined as
Supercurve Log2 (Raw) values. All the data points were
normalized for protein loading and transformed to linear
values.
The identification of proteins differentially
expressed in the different comparisons of overexpression/
down-regulation compared to control (fold change (FC <
-1.25 or FC >1.25) was performed.
Venny tool was used to compare between
differentially expressed genelists (http://bioinfogp.cnb.
csic.es/tools/venny/).
Network of protein interactions between
differentially expressed proteins (FC < -1.5 or FC>1.5)
was generated using STRING (http://string-db.org).

Cutaneous melanoma patients were included in
the study at John Wayne Cancer Institute under the
MORD-RTPCR-0995 protocol approved by the Western
Institutional Review Board (WIRB Protocol #20072107).
Informed consent was obtained from all subjects and the
experiments were performed according to the principles
set out in the WMA Declaration of Helsinki and the NIH
Belmont Report. Tissue specimens were de-identified and
coded according to HIPAA recommendations to ensure the
confidentiality of the patients.
IHC was performed on 5µm human melanoma
sections. Slides were deparaffinized, rehydrated, and
then antigen retrieval was performed using 10mM
sodium citrate buffer (pH 6.0) in a boiling water bath
for 20 min. The sections were then incubated in 10g/L
trichloroisocyanuric acid (Sigma-Aldrich) solution for
30 min at RT to bleach melanin [60]. After rinse with tap
water, endogenous peroxidase was blocked with hydrogen
peroxide for 10 min and nonspecific binding was blocked
with Protein Block serum-free solution (Dako, Glostrup,
Denmark) for 10 min. The sections were incubated
overnight with the anti-ANGPTL4 rabbit polyclonal Ab
(Proteintech Group, Inc, Rosemont, IL, USA) at a dilution
of 1:100 in a 4°C humidified chamber. Visualization was
performed using LSAB2 system-HRP (Dako) and Liquid
DAB+ Substrate Chromogen System (Dako) according
to the manufacturer’s instructions. After visualization,
the sections were counterstained with Gill’s hematoxylin
(Sigma-Aldrich) for 1.5 min at RT, dehydrated, and
mounted. After the IHC, photographs were taken using a
Nikon Eclipse Ti microscope and NIS elements software
(Nikon, Melville, NY, USA) and analyzed by ImageJ
software (National Institute of Health, version 1.50i).
The expression of ANGPTL4 was quantified using H
score system [61], which considers both the intensity and
percentage of positive cells. The score was calculated
using the formula 1x(% of 1+ cells)+2x(% of 2+
cells)+3x(% of 3+ cells).

Reverse phase protein array (RPPA)
1X106 melanoma cells were seeded for 24 hrs.
Then cells were harvested by Trypsin EDTA (Biological
Industries). Cell pellet was washed twice with phosphatebuffered saline (PBS) and lysed (1% Triton X-100,
50mM HEPES, pH 7.4, 150mM NaCl, 1.5mM MgCl2,
1mM EGTA, 100mM NaF, 10mM Na pyrophosphate,
1mM Na3VO4, 10% glycerol, protease and phosphatase
inhibitors). Protein concentration was adjusted to
1-1.5µg/µl and denatured by 1% SDS. Cell lysates were
two-fold-serial diluted for 5 dilutions (from undiluted
to 1:16 dilution) and arrayed on nitrocellulose-coated
slides in 11x11 format. Samples were probed with Ab
www.impactjournals.com/oncotarget

Reverse transcription quantitative real-time PCR
(RT-qPCR)
cDNA extraction and RT-qPCR were performed
as described previously [8]. For mRNA amplification,
primers were designed based on the GenBank
Nucleotide Database of the NCBI website: ANGPTL4:
S-5‘-CTGCGAATTCAGCATCTGCAA-3‘,
AS5‘-CCTCAGGTCTAGGTGCTTGT-3‘;
CLDN1:
75791

Oncotarget

S-5‘-AAGATGAGGATGGCTGTCATT-3‘,
AS5‘ATACCATGCTGTGGCAACTAA-3‘; human RS9:
S-5‘-CGGAGACCCTTCGAGAAATCT-3‘,
AS-5‘GCCCATACTCGCCGATCA-3‘. Amplification reactions
were performed with SYBR Green I (Thermo fisher
scientific, ABgene, Germany) in duplicates in Rotor-gene
6000TM (Corbett life science, Australia) and Rotor-Gene
Q software. PCR amplification was performed over 40
cycles (95ºC for 15 sec, 59ºC for 20 sec, 72ºC for 15 sec).

populations. After selection, puromycin was continuously
added to the culture.

Preparation of melanoma or brain cell CM
Melanoma, microglia, astrocyte or BEC were
cultured for 24 hrs. The cells were washed and starved for
24 hrs. CM was collected, centrifuged for 5 min at 1400
rpm and filtered (0.45μm).

Construction of the expression vector and stable
over-expression of ANGPTL4

Stimulation of melanoma cells with BDF for cell
viability analysis

The over-expression construct of human ANGPTL4
(NM_139314) was created by PCR amplification
of genomic DNA by Phusion® High-Fidelity DNA
polymerase (Thermo Fisher Scientific), using the
following primers (designed based on the GenBank
Nucleotide Database of the NCBI website): ANGPTL4:
S-5’-TCTCTCACCGGGTATGAGCGGTGCTCCGACG
GCC-3’, AS-5’-GTGTCTTAATTAACTAGGAGGCTG
CCTCTGCTGC-3’ The generated fragment was digested
with AgeI and PacI and ligated into the corresponding
sites of pQCXIP vector (Clontech Laboratories, Inc.,
Mountain View, CA, USA). PCR products of ANGPTL4
were sequenced and found to be identical to the published
sequence. Production of infectious viruses and melanoma
infection were performed as described previously [10].
To produce mCherry expressing cells, melanoma
cells were similarly transduced with a pQCXIN-mCherry
plasmid and were selected using 800μg/ml G418 Sulfate
(A.G. Scientific, Inc., San Diego, CA, USA).

Brains of BALB/c mice were harvested, minced
to pieces in starvation medium and put on non-tissue
culture dishes in 10ml of the same media for 48 hrs at
37°C, to allow the secretion of BDF. Then, supernatantes
were collected, centrifuged for 5 min at 1400 rpm,
filtered (0.45μm) and further diluted to a concentration of
1.6mg/ml. Melanoma cells, cultured 24 hrs prior to the
experiment, were treated with BDF for 72 hrs at 37°C.
Starvation medium was added to control melanoma cells.
After 72 hrs, cell death was determined following the
addition of 5µl of 5mg/ml DAPI using S1000Exi flow
cytometer (stratedigm, San Jose, CA, USA) and FlowJo
software.

Stimulation of melanoma cells with tumor growth
factor β1 (TGFβ1)
Melanoma cells were starved for 1 hr, then
stimulated for 4 hrs with 5ng/ml [62] recombinant human
TGFβ1 (PeproTech Inc., Rocky Hill, NJ, USA) at 37°C.
Control cells were treated with the same medium without
TGFβ1.

ANGPTL4 down-regulation in melanoma cells
The down-regulation of ANGPTL4 was established
using a mixture of four different pGIPZ vectors
containing shRNA sequences targeting ANGPTL4
mRNA (NM_139314) (RHS4430-200184490, RHS4430200245716, RHS4430-200246249 and RHS4430200243106; Thermo Fisher Scientific). A sh-non-silencing
pGIPZ vector (RHS4531) was used as a negative control.
To produce the infectious viruses, the 293T
packaging cell line was co-transfected using the
calcium phosphate method with the lentiviral plasmids
shANGPTL4-pGIPZ or the sh-non-silencing-pGIPZ,
packaging plasmid pCMV∆R8.2 and envelope plasmid
pVSV-G. After 48 hrs, the virus particles in the medium
were collected and filtered (0.45μm; Whatman GmbH).
Melanoma cells, seeded 24 hrs before infection,
were infected in the presence of 8µg/ml polybrene and
the virus-containing medium, which was afterwards
replaced with fresh growth medium. After 72 hrs 2µg/
ml puromycin (InvivoGen, San Diego, CA, USA) was
addedfor additional 7 days to select stably infected cell
www.impactjournals.com/oncotarget

Stimulation of melanoma cells with BDF for
ANGPTL4 expression analysis
BDF were prepared as mentioned above in 0.5%
bovine serum albumin (BSA) supplemented RPMI1640, after 24 hrs of incubation at 37°C. Melanoma cells,
cultured 24 hrs prior to the experiment, were treated with
BDF for 24 hrs at 37°C. 0.5% BSA supplemented RPMI1640 was added to control cells. Cells were analyzed for
ANGPTL4 expression using RT-qPCR.

Viability assay (XTT)
Cell Proliferation Kit (XTT, Biological industries)
was used according to the manufactures’ instructions. To
obtain the relative cell viability, the optical density (OD)
of the treated cells (in each time point) was divided by the
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OD of the non-treated cells at the same time point of the
experiment.

fields under fluorescence microscopy in duplicates using
OlympusIX53 inverted microscope (Olympus).

Adhesion to BEC

Gelatin zymography analysis

Adhesion of melanoma cells to BEC was performed
as described previously [10]. Adhesion of GFP-expressing
cells was measured at wavelength of 490/530. Adhesion
of mCherry-expressing cells was measured at wavelength
of 590/645. To obtain the cell relative adhesion capacity,
the OD of the adherent cells was divided by the OD of the
total cells plated.

4.5X105 melanoma cells were plated in 24-well
plates for 24 hrs, then growth medium was removed
and replaced by 500µl serum-free RPMI-1640 medium
for additional 24 hrs. To determine MMP-2 activity,
CM was collected and subjected to gelatin and collagen
zymography assay as described previously [64].

Migration through extracellular matrix

Orthotopic inoculation of tumor cells and in vivo
tumorigenicity and metastasis formation assays

1X105 melanoma cells were loaded onto collagencoated transwell inserts (8μm; Corning Costar Corp.,
New York, NY, USA) and allowed to migrate for 24 hrs
towards starvation medium. Then, the upper side of the
apical chamber was scraped gently with cotton swab, to
remove non-migrating cells. Cells at the bottom side of
the transwell inserts were fixed with ice-cold methanol for
5 minutes. Migrating cells were stained with Dif-stain Kit
(Kaltek, Padova, Italy), according to the manufacturer‘s
instructions. The number of melanoma cells transmigrating
to the underside of the membrane was determined in each
experiment by counting at least five independent fields
in duplicates using OlympusIX53 inverted microscope
(Olympus, Center Valley, PA, USA).

To generate subcutaneous tumors, 1X106 cells in
100μl of 5% FCS supplemented RPMI-1640 medium were
inoculated subdermally into the right thigh of male nudeBALB/c mice.
To test the tumorigenic properties of derived cell
lines, subcutaneous tumors were measured once a week
using a caliper. Tumor volume was obtained by the
ellipsoid volume calculation formula 0.5X(lengthXwidth2)
[65, 66]. Mice were weighed weekly. Mice were
killed when moribund, and brains were harvested and
immediately frozen and stored at -70°C, until used
for RNA extraction. Detection of human cells (micrometastases) in mouse brain by RT-qPCR was performed
as described previously [8].

Transendothelial migration through a BBB model

Statistical analysis

In vitro BBB models consisting of BEC co-cultured
with astrocytes are utilized for studying the properties of
the BBB [63].
5X104 BEC were loaded onto collagen-coated
transwell inserts (8μm; Corning Costar Corp.) and allowed
to create a monolayer for 48 hrs (illustrated in Figure 2G).
Simultaneously, 5X104 astrocytes were separately plated
at the bottom of Poly-L-Lysine-coated 24-wells. 24 hrs
later astrocytes were washed and starved for another
24 hrs, to allow secretion of astrocyte-derived soluble
factors into the medium. 48 hrs after seeding of BEC
and astrocytes, 1X105 mCherry-expressing melanoma
cells were loaded onto the endothelial monolayer and
allowed to migrate towards the astrocytes for 24 hrs.
Then, the upper side of the apical chamber was scraped
gently with cotton swab, to remove non-migrating cells.
Cells at the bottom side of the transwell inserts were
fixed with 4% paraformaldehyde and mounted with DAPI
Fluoromount-G (SouthernBiotech, Birmingham, AL,
USA). The number of melanoma cells transmigrating
to the underside of the membrane was determined in
each experiment by counting at least five independent

Paired or unpaired Student t test was used to
compare in vitro and in vivo results.
For the IHC experiments, statistical differences on
the H-score values were analysed by using the KruskalWallis test among the groups. Additionally, the SteelDwass method was used to further compare between
groups that were considered statistically significant. The
statistical analyses were performed with EZR (Saitama
Medical Centre, Jichi Medical University, Saitama, Japan,
version 1.32), a graphical user interface for R (The R
Foundation for Statistical Computing, Vienna, Austria).
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